ACXP News and Press, Acurx Pharmaceuticals Inc. From 04/25/24

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference PR Newswire STATEN ISLAND, N.Y. , April 25, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the...

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , April 23, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Co...

Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New York on April 8th-9th, 2024. The event is expected to feature 80 companies presenting in...

2024-03-19 10:23:08 ET More on Acurx Pharmaceuticals Acurx Sell-Off Presents Opportunity Before Upcoming Data Release Acurx stock plunges 26% amid Phase 2 data release for C. diff drug Read the full article on Seeking Alpha For further details see: Acurx ...

2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...

2024-03-18 11:19:09 ET Acurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Conference Call March 18, 2024 08:00 AM ET Company Participants Robert Shawah - CFO David Luci - President and CEO Robert DeLuccia - Executive Chairman Conference Call Participants ...

2024-03-18 11:15:57 ET More on Acurx Pharmaceuticals Acurx Sell-Off Presents Opportunity Before Upcoming Data Release Acurx stock plunges 26% amid Phase 2 data release for C. diff drug ELAB, KIND and RLX among pre-market losers Seeking Alpha’s Quant Ra...

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update PR Newswire STATEN ISLAND, N.Y. , March 18, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clini...

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update PR Newswire STATEN ISLAND, N.Y. , March 4, 2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP...

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development PR Newswire As previously announced, planning is underway with FDA to advance ibezapo...